Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Current Deferred Revenue (2016 - 2017)

Aptevo Therapeutics (APVO) has disclosed Current Deferred Revenue for 3 consecutive years, with $3.7 million as the latest value for Q3 2017.

  • Quarterly Current Deferred Revenue rose 478.12% to $3.7 million in Q3 2017 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Sep 2017, up 478.12% year-over-year, with the annual reading at $811000.0 for FY2016, 78.9% down from the prior year.
  • Current Deferred Revenue hit $3.7 million in Q3 2017 for Aptevo Therapeutics, up from $1.4 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $3.8 million in Q4 2015 to a low of $394000.0 in Q2 2016.
  • Historically, Current Deferred Revenue has averaged $1.7 million across 3 years, with a median of $878000.0 in 2017.
  • Biggest five-year swings in Current Deferred Revenue: tumbled 78.9% in 2016 and later skyrocketed 478.12% in 2017.
  • Year by year, Current Deferred Revenue stood at $3.8 million in 2015, then crashed by 78.9% to $811000.0 in 2016, then soared by 356.23% to $3.7 million in 2017.
  • Business Quant data shows Current Deferred Revenue for APVO at $3.7 million in Q3 2017, $1.4 million in Q2 2017, and $878000.0 in Q1 2017.